Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide 2.4 mg) is associated with meaningful reductions in blood pressure in clinical trials, alongside weight loss — most participants in the STEP programme saw systolic blood pressure fall by around 5–6 mmHg on average. That said, it is a prescription-only medicine and whether it is clinically appropriate for you depends on a full assessment by a prescriber, not just your blood pressure reading. The relationship between Wegovy and blood pressure is more nuanced than a headline number suggests, so it is worth understanding what drives the change, who benefits most, and when to keep a closer eye on readings.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The short answer is yes, for most people, and weight loss is the primary driver. When body weight falls, cardiac output drops, arterial stiffness tends to ease, and the kidneys excrete sodium more efficiently, all of which contribute to lower blood pressure. In the STEP 1 trial, published in the New England Journal of Medicine, participants taking semaglutide 2.4 mg lost around 15% of body weight over 68 weeks, and systolic blood pressure fell by roughly 5–6 mmHg compared with placebo. Diastolic pressure fell by a smaller margin.
There is also some evidence of a modest direct effect on blood pressure beyond weight loss alone, possibly related to GLP-1 receptor activity on the kidneys and sympathetic nervous system, though the clinical significance of this pathway in humans is still being studied. Practically speaking, the weight-loss effect dominates for most people. You can read more about whether Wegovy helps blood pressure in detail, including who saw the greatest reductions in trials.
It is important to hold the trial averages lightly. A 5–6 mmHg reduction is meaningful at population scale but some people see more, some see less, and a handful see no change. Hypertension is one of the weight-related conditions that can meet the private licence eligibility threshold (BMI 27 or above with a qualifying comorbidity), so it often features in consultations.
Potentially, yes, and this is one of the more practical points for anyone already on antihypertensives. As blood pressure falls during treatment, a dose of amlodipine or ramipril that was well-calibrated before may start to do too much. Symptoms like lightheadedness on standing, tiredness, or feeling faint could be a sign your antihypertensive dose needs reviewing rather than a side effect of Wegovy itself.
NHS England's guidance on weight-management injections specifically flags this point: patients on blood pressure medicines should have their readings monitored and their prescriptions reviewed as weight changes. That review sits with your GP or the clinician managing your hypertension, not something to adjust without guidance. At nume, sorry. At nume, our prescribers ask about existing blood pressure medication at consultation and flag this for ongoing monitoring. Worth raising with your GP proactively once treatment is underway.
For a closer look at how readings tend to shift during treatment, the Wegovy effect on blood pressure page covers the week-by-week picture.
Low blood pressure is not a common effect, but it can happen in specific circumstances. The most likely scenario is not a pharmacological one: significant nausea, vomiting, or reduced appetite can lead to dehydration, which drops blood pressure transiently. This tends to be most relevant in the first few weeks of treatment or after a dose step-up, when GI side effects are most prominent.
People who are already on the lower end of normal blood pressure, or who have a history of postural hypotension (pressure dropping when standing), should mention this during their consultation. A small number of people experience dizziness or lightheadedness that traces back to fluid intake rather than the medicine itself, drinking enough water, especially during warm weather or exercise, matters more than many people expect. If dizziness is persistent rather than occasional, that warrants a call to your prescriber or GP.
The relationship between semaglutide and low blood pressure has its own dedicated page for anyone who wants the fuller picture, and the guide to avoiding low blood sugar on Wegovy covers overlapping symptoms that are sometimes confused with a blood pressure dip.
If you have diagnosed hypertension or are on blood pressure medication, checking your readings every two to four weeks during the first few months of Wegovy treatment is sensible, your GP surgery or a home blood pressure cuff works equally well. Take the reading at the same time each day (morning, before food, after a few minutes sitting quietly, the same logic as keeping your weekly injection on the same day each week, tucked in the fridge door as a reminder). Log the numbers so your GP has a clear trend rather than a single data point.
If you do not have diagnosed hypertension and your starting blood pressure is normal, routine daily monitoring is not necessary. That said, if you develop persistent headaches, visual disturbance, or chest tightness at any point during treatment, seek medical attention promptly, do not wait for your next scheduled review.
Anyone thinking about starting semaglutide for weight management can get a thorough picture of the medicine on the semaglutide overview page, or explore treatment options more broadly on the weight-loss treatments page. If you have specific questions about blood pressure and high readings, the Wegovy and high blood pressure page addresses that context directly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.